# What Should a GLP-1 Provider Actually Do? Five Pillars | This GLP The EASO position statement on integrating incretin-based therapies names five pillars of good care — and a reader can hold any seller to all five. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/what-should-a-glp1-provider-actually-do Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Formats # What Should a GLP-1 Provider Actually Do? Five Pillars A European specialist society set out what proper care around these drugs requires. It was not written about online sellers, which is what makes it useful against them. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min read The EASO Integration Framework · Right · Patient · Right · Care · Right · Workforce · Right · Data · Right · Access · Interdependent, in the authors’ description — not a menu to pick from **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - The European Association for the Study of Obesity published a position statement on how these drugs should be delivered. - It names an Integration Paradox: the therapies have advanced faster than the systems needed to use them well. - Its framework has five interdependent pillars — Right Patient, Right Care, Right Workforce, Right Data, Right Access. - The statement is about European health systems, not about telehealth sellers, and says nothing about this market. - Read as a checklist, it is a useful one, and most sellers here publish nothing against most of it. There is a published answer, and it was not written with this market in mind. The European Association for the Study of Obesity set out five interdependent pillars. Right Patient. Right Care. Right Workforce. Right Data. Right Access. It names an Integration Paradox. The therapies advanced faster than the systems needed to use them well. That is a statement about health systems, not about telehealth sellers. Read as a checklist it is still useful. Most sellers here publish nothing against most of it. That silence is measured three ways. There is [whether disclosure is a trait a seller has](https://thisglp.com/research/is-seller-disclosure-a-trait). There is [how invisible compounded use is in the record](https://thisglp.com/research/how-many-people-use-compounded-glp1-drugs) [\[2\]](https://thisglp.com/research/what-should-a-glp1-provider-actually-do#ref-2), and in [what the dose-error reports list](https://thisglp.com/research/glp1-dose-errors-in-adverse-reports). A specialist society has written down what it thinks good care around these drugs requires. It is not addressed to anybody selling them online. That is part of why it is worth reading here. It describes a standard set without this market in mind, and [what sellers publish](https://thisglp.com/research/what-glp1-sellers-do-not-publish) can be laid against it. ## The paradox they name European health systems vary in workforce capability, multidisciplinary care, reimbursement, access and monitoring infrastructure. [\[1\]](https://thisglp.com/research/what-should-a-glp1-provider-actually-do#ref-1) The authors argue that therapeutic innovation has outpaced the structures needed to use it well. They call that mismatch the EASO Integration Paradox. Their closing position is unambiguous. Worth stating before anything else. The question is no longer whether incretin-based therapies should be used. It is how to implement them responsibly, inside comprehensive obesity care pathways. This is a document in favor of the drugs. ## The five pillars Right Patient. Right Care. Right Workforce. Right Data. Right Access. The authors describe them as interdependent. That is the load-bearing word. The framework is not a menu a provider picks two from. Alongside it they set out a research and implementation agenda: real-world evidence, harmonized monitoring, workforce development, pharmacovigilance, and equitable access. What follows is ours, not theirs EASO is writing about national health systems. It makes no claim about telehealth sellers, and this page is not putting one in its mouth. But a reader choosing where to buy has five headings here. Nobody wrote them for a marketing department, and they answer a question a price comparison cannot: what should surround this prescription? ## Reading the pillars against a checkout Right Patient asks whether the person in front of you should be on this drug at all. An intake form can do a version of that. How good a version is not something a buyer can inspect from outside. Right Care and Right Workforce are about what surrounds the prescription — dietetic input, behavioral support, someone to call. This site has covered [a remote program that supplied several of those](https://thisglp.com/research/telehealth-glp1-program-trial) and produced results comparable to trials. It can be done remotely. It usually is not, and almost no seller here describes what they provide. Right Data means monitoring and follow-up that goes somewhere. Right Access is the one this market arguably improves on a national system. It makes the drug obtainable to people no insurer would cover — while leaving the other four pillars to the buyer. ## What to do with a framework Use it as five questions rather than as a verdict. Who decided I should take this, and on what basis? What comes with it besides the drug? Who do I contact when something changes? What is being measured, and by whom? And what happens when I cannot pay? Most sellers on this roster answer none of those. That is measurable rather than rhetorical. [the disclosure scorecard](https://thisglp.com/tools/what-sellers-publish) counts what each one says, and [the census of silence](https://thisglp.com/tools/questions-they-leave-open) counts what they leave to you. A framework written for health ministries turns out to be a decent shopping list. For a concrete care model, [Form Health](https://thisglp.com/reviews/form-health) describes monthly clinician and dietitian video visits plus messaging in its [FAQ](https://www.formhealth.co/faqs). Those are services a reader can ask about elsewhere. They do not establish that any particular program meets every EASO pillar or delivers the same outcomes. ## Frequently asked What are the five pillars? Right Patient, Right Care, Right Workforce, Right Data and Right Access. The authors describe them as interdependent rather than as separate options. Does the statement criticize telehealth? No. It is addressed to European health systems and says nothing about online sellers. The comparison to a checkout on this page is this site's, not EASO's. Is it opposed to the drugs? The opposite. Its closing position is that the question is no longer whether these therapies should be used but how to implement them responsibly. How do I use it as a buyer? As five questions: who decided I should take this, what comes with it besides the drug, who do I contact when something changes, what is being measured, and what happens if I cannot pay. ## Sources 1. \[1\] Correia JC, et al. (2026). Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement The Lancet Regional Health. Europe. [PMID 42733510](https://pubmed.ncbi.nlm.nih.gov/42733510/) 2. \[2\] Hendrix N, Velásquez EE, Pham H, Bazemore A (2025). Documentation of Compounded GLP-1 Receptor Agonists in a Large Primary Care Dataset Pharmacoepidemiology and Drug Safety. [PMID 41024632](https://pubmed.ncbi.nlm.nih.gov/41024632/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Formats - [ Label-approved sites and semaglutide exposure · Abdomen · 2 in. from navel · similar · Thigh · under the skin · similar · Upper arm · under the skin · similar · Blood levels, not weight loss. No trial randomized people to a site. ### Where Should You Inject Ozempic? Abdomen, Thigh or Arm Gave the Same Exposure ](https://thisglp.com/research/where-should-you-inject-ozempic) - [ The labeled ladder — four weeks on every rung · 0.25 · wk 1–4 · 0.5 · wk 5–8 · 1 · wk 9–12 · 1.7 · wk 13–16 · 2.4 · wk 17+ · Milligrams weekly. No compounded product carries this label. ### Semaglutide Starting Dose: 0.25 mg, and What Compounding Changes ](https://thisglp.com/research/semaglutide-starting-dose) - [ Approved: weight management, US, April 2026 · Phase 3 in progress, not approved: · sleep apnea · hypertension · urinary incontinence · osteoarthritis pain · artery disease · A daily tablet, not a peptide, not an injection. ### Is There a GLP-1 Pill That Works? Two Tablets, Two Different Answers ](https://thisglp.com/research/does-the-glp1-pill-work-as-well-as-the-injection)